US Pharma MarketingThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
Source: BioPharma Dive